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ABSTRACT
As the number of prescribed drugs is constantly
rising, drug–drug interactions are an important
issue. The simultaneous administration of several
drugs can cause severe adverse effects based on
interactions with the same metabolizing enzyme(s).
The Transformer database (http://bioinformatics.
charite.de/transformer) contains integrated infor-
mation on the three phases of biotransformation
(modification, conjugation and excretion) of 3000
drugs and >350 relevant food ingredients (e.g.
grapefruit juice) and herbs, which are catalyzed by
400 proteins. A total of 100 000 interactions were
found through text mining and manual validation.
The 3D structures of 200 relevant proteins are
included. The database enables users to search
for drugs with a visual display of known interactions
with phase I (Cytochrome P450) and phase II
enzymes, transporters, food and herbs. For each
interaction, PubMed references are given. To
detect mutual impairments of drugs, the drug-
cocktail tool displays interactions between
selected drugs. By choosing the indication for a
drug, the tool offers suggestions for alternative
medications to avoid metabolic conflicts. Drug
interactions can also be visualized in an interactive
network view. Additionally, prodrugs, including their
mechanisms of activation, and further information
on enzymes of biotransformation, including 3D
models, can be viewed.
INTRODUCTION
The number of prescribed drugs is rising (1). A study
revealed that 87.1% of people >50 years of age take at
least one drug per day, and 43.3% take >5 (2).
Polypharmacy, which is defined as the regular use of five
or more drugs, leads to an increased risk of adverse drug
reactions (ADRs). The frequency of ADR is associated
with the number of drugs prescribed (3). Among
hospitalized patients, ADRs have an incidence of 6.7%
and are the fifth commonest cause of death (4). One
possible cause for ADR might be the individual variance
of drug metabolism (5), and age-related changes make
elderly patients more sensitive to ADRs (6). The informa-
tion is widely scattered over the scientific literature.
A knowledge base of xenobiotic metabolism and the
effect of polymorphisms could prevent ADR and cases
of death.
Xenobiotic metabolism and detoxification (especially
for drugs) are separated into three different phases of
reaction. Only a few xenobiotics are excreted unchanged
in urine or feces without any metabolic degradation.
Phase I and phase II reactions convert compounds to
more water-soluble and often less active derivatives to
increase excretion. Thereby, phase I reflects the produc-
tion of reactive groups through oxidation and is primarily
managed by the Cytochrome P450 family (CYP) of
enzymes (7). Subsequently, the reactive groups are used
to conjugate small polar molecules (phase II) to increase
the polarity. Six enzyme families that provide the detoxi-
fication and excretion of xenobiotics mainly realize the
conjugation (8).
Transporters (phase III) play a crucial role in pharma-
cokinetics by enabling the migration of hydrophilic mol-
ecules, which cannot penetrate cellular membranes. Kell
et al. showed that the majority of drugs enter cells through
at least one transporter (9). Those proteins form a trans-
membrane channel lined with hydrophilic amino acid side
chains spanning the lipid bilayer (10). Two major protein
superfamilies are known: 49 ATP-binding cassette trans-
porters (ABC) (11) and 362 solute carriers (SLC) (12).
These are important for absorption, distribution and
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excretion of drugs (13) and are involved in a broad range
of physiological processes (10).
Eukaryotic ABC transporters are predominantly expor-
ters, which require energy released by ATP hydrolysis.
One problem is multidrug resistance, which is caused by
active transporters. Unfortunately, 40% of human tumors
develop resistance to chemotherapeutics by overexpressing
ABC proteins (14). The SLC transporters facilitate passive
diffusion along the concentration gradient or use concen-
tration gradients from other substrates as a symporter or
antiporter (12).
Another issue related to drug metabolism and ADR is
prodrugs. Prodrugs have to be converted to active drugs
by metabolic conversion (15). In general, prodrugs are
non-toxic and need to have their chemical structure
changed to enable their inherent medical capability.
However, problems in conversion can also lead to un-
desired side effects. For example, the antihistamine
terfenadine is a potent hERG blocker as a prodrug and
a slow conversion can cause cardiac toxicity (16).
Prodrugs can be activated by photo irradiation (17), a
change in pH (18) and enzymes, such as esterases or CYPs
(19,20). Many prodrugs are activated by hydrolysis with
the aid of esterases or phosphatases. Thereby, gastric in-
testinal tolerance and pharmacokinetics can be improved,
but the targeting of drugs to specific cells or tissues
cannot. The activation of prodrugs by CYPs might be a
better approach (21).
Not only can drugs participate in the alteration of drug
metabolism but food and herbs also have a proven influ-
ence; e.g. furanocoumarins in grapefruit inhibit intestinal
CYP3A4 and organic anion-transporting polypeptides
1A2 (22,23).
More than 350 ingredients in food and drink, such as
broccoli, alcohol and char-grilled meat, as well as herbal
medicine, such as St John’s wort, are known to alter drug
responses.
A comprehensive resource that combines scientific in-
formation on phase I and phase II enzymes, transporter
enzymes, prodrugs, food and herbs could help to improve
research in this field and prevent ADR.
MATERIALS AND METHODS
Text mining
We created a text mining approach using semantic web
standards. To develop a specialized text mining pipeline,
we first downloaded Medline/PubMed data from the
NCBI FTP site in xml-format. Using the search engine
library Apache Lucene (http://lucene.apache.org) and a
tool kit for processing text with computational linguistics
(http://alias-i.com/lingpipe), the data was indexed. The
search engine comprises comprehensive lists of chemical
compounds and drug names (24), metabolic enzymes (25)
and transporters (26), including their various synonyms.
Additionally, we added a list of common interaction
terms, such as ‘activate’, ‘inhibit’, and ‘metabolize’. The
search engine, written in Java, dynamically queries the
indexed data and produces a structured query language
(SQL) file containing the text mining hits. A query
example is:
(DrugSynonym [TI] AND TransformerSynonym
[TI]) OR
(DrugSynonym [abstract] AND TransformerSynonym
[abstract]) OR
(DrugSynonym [abstract] AND InteractionTerm AND
TransformerSynonym [abstract])
The positional distance between the different terms had to
be restricted to reduce false-positive hits, when terms
occurred far from each other in the abstract. The 22 500
records found were scored as rule-based. Duplicates were
removed and a team of scientists manually processed
12 427 articles found in PubMed. Further details about
the text mining approach can be found on the Web site
in the frequently asked questions (FAQs) section.
Database
The database was designed as a relational database on a
MySQL server. To allow chemical functionality, such as
handling chemical data within MySQL, the MyChem
package was included.
Information about 3000 CYP drug interactions and
2000 polymorphisms were extracted from the SuperCYP
database (27). SuperCYP is a database with a focus on
human CYPs. However, there are many other important
enzymes in the metabolism of xenobiotics, such as trans-
porters or phase II enzymes.
DATABASE FEATURES
Over 100 000 interactions were revealed. In the 12 427 art-
icles found in PubMed, 769 drugs were attributed to those
phase II enzymes that are involved in drug metabolism.
Text mining was also performed for prodrugs, trans-
porters and food. We found 125 prodrugs described in
890 PubMed articles together with their mechanism of
activation, accompanying enzymes, chemical structure
and identification numbers. Furthermore, 500 drug-
transporters and 150 food interactions were identified.
Additionally, 200 3D structures were collected for
transporters, CYPs and phase II enzymes.
The database includes four main functionalities. To
provide an overview of these, a comprehensive FAQs
section was created, which is helpful for first-time users.
Depending on the user’s interest or needs (e.g. clinicians,
researchers), differentways tobrowse thedatawereenabled.
Prodrugs
Prodrugs can be identified directly by entering the name,
PubChemID, CAS number or ATC code, as well as by
choosing a mechanism of activation, such as ring opening
or carboxylation.
Drugs
To view the metabolism of particular drugs, users can
search directly by entering the name, PubChemID or











Figure 1. Functionalities of the ‘Transformer database’. (A) Composition of a drug-cocktail. An example of a PubMed reference is shown. PubMed
references can be viewed by clicking on ‘S’, ‘Inh’ or ‘Ind’ in the result table. (B) Clicking on ‘Get Interactions’ leads to a result table, which shows the
interactions between the drugs. (C) By choosing the indications of the drugs via ATC-code the user receives specific alternatives. (D) By clicking on
an enzyme (e.g. CYP3A4), detailed information on the enzyme, including drug interactions, are shown. (E) The 3D structures of all enzymes can be
viewed (e.g. CYP3A4). (F) Network views are provided for each enzyme and compound.











CAS number. Based on the WHO classification system,
which classifies drugs into different groups according to
Anatomical site of action, Therapeutical effect and
Chemical structure (ATC), a tree with all of the drugs
contained in the database can be viewed in their ATC
group.
Cocktail
This tool enables users to see drug interactions of an in-
dividually composed drug cocktail (Figure 1A). If >1 drug
interacts with the same enzyme, lines of the interaction
table are shown in yellow, orange, red and dark red
(Figure 1B). In the header of each column, the indication
for the drugs can be chosen and the database will provide
alternative drugs that are metabolized by different
enzymes (Figure 1C). PubMed references are available
by clicking on the interaction. Additionally, food inter-
actions, as well as elimination half-life (EHL) times and
Q0 values are displayed. A Q0 value (extrarenal excretion)
of <0.3 is shown in green because those drugs are, to a
large extent, excreted in the unchanged form. Clicking
‘Display network’ presents these interactions in a
network view based on Cobweb (28).
Biotransformation
To find drugs that are metabolized by specific phase I,
phase II or transporter enzymes, users can perform a
search by clicking on ‘Biotransformation’. This page
provides (homology modeled) 3D structures of all
enzymes (Figure 1E). Furthermore, a list of interacting
drugs can be viewed in a table (Figure 1D) or in a
network view (Figure 1F).
DATABASE USAGE
The following case illustrates the need to detect interactions
with the help of the Transformer database. A five-year-old
child died froma fatal opioid toxicity. Shewas inadvertently
administered a high dose of hydrocodone (an antitussive
drug) while suffering from a cold. Additionally, she was
administered clarithromycin for an ear infection and
valproic acid for seizures. The postmortem blood screen
revealed an excessively high-hydrocodone level and, in
contrast, barely measurable hydromorphone (biotrans-
formation metabolite of hydrocodone) concentration (29).
Hydrocodone is metabolized by CYP2D6, CYP3A4 and
afterwards by UGT. There were three reasons for the low
metabolism rate:
(1) CYP-polymorphism: the child was found to be a
CYP2D6 poor metabolizer,
(2) inhibition of CYP3A4 by clarithromycin and
(3) inhibition of UGT by valproic acid.
Figure 1B shows the Transformer database results for
this drug combination. All interactions described in this
case are displayed and colored because of enzyme
overload. Nevertheless, parts of the available information
of drug–enzyme interactions are experimental data and
offer no evidence for drug interactions in humans and
clinical work, although Q0 and elimination half-life times
could be relevant. The Transformer database, however,
provides a platform for detecting mutual drug impair-
ments and could help to appraise the drug response. The
database is a comprehensive resource on drug enzyme/
transporter interactions and could be a sound starting-
point for further research.
The database will be updated yearly to add new drugs/
compounds and interactions.
AVAILABILITY
The Transformer database is publicly available via http://
bioinformatics.charite.de/transformer and should be used
under the terms of the Creative Commons Attribution-
Noncommercial-Share Alike 3.0 License.
FUNDING
Funding for open access charge: SynSys (EU Framework
7) and DKTK (BMBF), BMBF Immunotox.
Conflict of interest statement. None declared.
REFERENCES
1. Banerjee,A., Mbamalu,D., Ebrahimi,S., Khan,A.A. and Chan,T.F.
(2011) The prevalence of polypharmacy in elderly attenders to an
emergency department—a problem with a need for an effective
solution. Int. J. Emerg. Med., 4, 22.
2. Morgan,T.K., Williamson,M., Pirotta,M., Stewart,K., Myers,S.P.
and Barnes,J. (2012) A national census of medicines use: a
24-hour snapshot of Australians aged 50 years and older.
Med. J. Aust., 196, 50–53.
3. Sato,I. and Akazawa,M. (2013) Polypharmacy and adverse
drug reactions in Japanese elderly taking antihypertensives: a
retrospective database study. Drug Healthc. Patient Saf., 5,
143–150.
4. Lazarou,J., Pomeranz,B.H. and Corey,P.N. (1998) Incidence of
adverse drug reactions in hospitalized patients: a meta-analysis
of prospective studies. JAMA, 279, 1200–1205.
5. Phillips,K.A., Veenstra,D.L., Oren,E., Lee,J.K. and Sadee,W.
(2001) Potential role of pharmacogenomics in reducing adverse
drug reactions: a systematic review. JAMA, 286, 2270–2279.
6. Marusic,S., Bacic-Vrca,V., Obreli Neto,P.R., Franic,M.,
Erdeljic,V. and Gojo-Tomic,N. (2013) Actual drug-drug
interactions in elderly patients discharged from internal medicine
clinic: a prospective observational study. Eur. J. Clin. Pharmacol.,
69, 1717–1724.
7. Guengerich,F.P. (2001) Common and uncommon cytochrome
P450 reactions related to metabolism and chemical toxicity.
Chem. Res. Toxicol., 14, 611–650.
8. Jakoby,W.B. and Ziegler,D.M. (1990) The enzymes of
detoxication. J. Biol. Chem., 265, 20715–20718.
9. Kell,D.B., Dobson,P.D., Bilsland,E. and Oliver,S.G. (2013)
The promiscuous binding of pharmaceutical drugs and their
transporter-mediated uptake into cells: what we (need to) know
and how we can do so. Drug Discov. Today, 18, 218–239.
10. Yan,Q. (2003) Pharmacogenomics of membrane transporters an
overview. Methods Mol. Biol., 227, 1–20.
11. Velamakanni,S., Wei,S.L., Janvilisri,T. and van Veen,H.W. (2007)
ABCG transporters: structure, substrate specificities and
physiological roles:a brief overview. J. Bioenerg. Biomembr., 39,
465–471.
12. He,L., Vasiliou,K. and Nebert,D.W. (2009) Analysis and
update of the human solute carrier (SLC) gene superfamily.
Hum. Genomics, 3, 195–206.
13. Ishikawa,T., Tamura,A., Saito,H., Wakabayashi,K. and
Nakagawa,H. (2005) Pharmacogenomics of the human ABC











transporter ABCG2: from functional evaluation to drug molecular
design. Naturwissenschaften, 92, 451–463.
14. Landry,Y. and Gies,J.P. (2008) Drugs and their molecular targets:
an updated overview. Fundam. Clin. Pharmacol., 22, 1–18.
15. Albert,A. (1958) Chemical aspects of selective toxicity. Nature,
182, 421–422.
16. Yap,Y.G. and Camm,A.J. (2002) Potential cardiac toxicity of
H1-antihistamines. Clin. Allergy Immunol., 17, 389–419.
17. Dorman,G. and Prestwich,G.D. (2000) Using photolabile ligands
in drug discovery and development. Trends Biotechnol., 18, 64–77.
18. Simplicio,A.L., Clancy,J.M. and Gilmer,J.F. (2007) Beta-
aminoketones as prodrugs with pH-controlled activation.
Int. J. Pharm., 336, 208–214.
19. Huttunen,K.M., Mahonen,N., Raunio,H. and Rautio,J. (2008)
Cytochrome P450-activated prodrugs: targeted drug delivery.
Curr. Med. Chem., 15, 2346–2365.
20. Topf,N., Worgall,S., Hackett,N.R. and Crystal,R.G. (1998)
Regional ‘pro-drug’ gene therapy: intravenous administration of
an adenoviral vector expressing the E. coli cytosine deaminase
gene and systemic administration of 5-fluorocytosine suppresses
growth of hepatic metastasis of colon carcinoma. Gene Ther., 5,
507–513.
21. Ortiz de Montellano,P.R. (2013) Cytochrome P450-activated
prodrugs. Future Med. Chem., 5, 213–228.
22. Bressler,R. (2006) Grapefruit juice and drug interactions.
Exploring mechanisms of this interaction and potential toxicity
for certain drugs. Geriatrics, 61, 12–18.
23. Uno,T. and Yasui-Furukori,N. (2006) Effect of grapefruit juice in
relation to human pharmacokinetic study. Curr. Clin. Pharmacol.,
1, 157–161.
24. Wang,Y., Xiao,J., Suzek,T.O., Zhang,J., Wang,J. and Bryant,S.H.
(2009) PubChem: a public information system for analyzing
bioactivities of small molecules. Nucleic Acids Res., 37,
W623–W633.
25. Sim,S.C. and Ingelman-Sundberg,M. (2010) The Human
Cytochrome P450 (CYP) Allele Nomenclature website: a
peer-reviewed database of CYP variants and their associated
effects. Hum. Genomics, 4, 278–281.
26. Saier,M.H. Jr, Yen,M.R., Noto,K., Tamang,D.G. and Elkan,C.
(2009) The Transporter Classification Database: recent advances.
Nucleic Acids Res., 37, D274–D278.
27. Preissner,S., Kroll,K., Dunkel,M., Senger,C., Goldsobel,G.,
Kuzman,D., Guenther,S., Winnenburg,R., Schroeder,M. and
Preissner,R. (2010) SuperCYP: a comprehensive database on
Cytochrome P450 enzymes including a tool for analysis of
CYP-drug interactions. Nucleic Acids Res., 38, D237–D243.
28. von Eichborn,J., Bourne,P.E. and Preissner,R. (2011) Cobweb: a
Java applet for network exploration and visualisation.
Bioinformatics, 27, 1725–1726.
29. Madadi,P., Hildebrandt,D., Gong,I.Y., Schwarz,U.I.,
Ciszkowski,C., Ross,C.J., Sistonen,J., Carleton,B.C.,
Hayden,M.R., Lauwers,A.E. et al. (2010) Fatal hydrocodone
overdose in a child: pharmacogenetics and drug interactions.
Pediatrics, 126, e986–e989.





C on January 2, 2014
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
